• Search
  • News
  • Press releases
  • Contact
  • Work with us
Logo
  • About us
    • Idea and vision
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • R&D
    • Tech platform: Abiprot® antibody platform
    • Scientific publications
  • Portfolio
    • Pipeline
    • Programs
  • Corporate Governance
    • Rights issue 2023
    • ANNUAL GENERAL MEETING 2022
    • Extra General Meeting 2022
    • Previous Annual General Meetings
    • Board of Directors and Management
    • Nomination Committee
    • Articles of Association
  • Investor Relations
    • Financial Reports
    • Annual Reports for the years 2016–2021
    • Convertible bonds rights issue 2022
    • Investor Relations contact
  • Partnering
    • Partnership & Collaboration
    • Partnering Contact
      Oblique
      News
      General Meeting 2020

      General Meeting 2020

      Oblique Therapeutics AB – Notice to the annual general meeting 2020

      Site logo

      Contact

      Oblique Therapeutics AB (publ)info@obliquet.com

      Gothenburg

      413 46 Göteborg

      Arvid Wallgrens Backe 20

      Sweden

      Stockholm

      113 52 Stockholm

      Döbelnsgatan 64

      Sweden

      Menu

      • Vision
      • About us
      • R&D
      • Portfolio
      • Corporate Governance
      • Investor Relations
      • Privacy Policy
      • Disclaimer
      • Contact

      About

      Oblique Therapeutics AB (publ) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses Abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.

      Follow us on LinkedIn

      Copyright © 2021 Oblique Therapeutics AB (publ)